Financials

  • Market Capitalization 343.86 M
  • Employee 88
  • Founded 1994
  • CEO Craig A Tooman
  • Website www.silence-therapeutics.com
  • Headquarter United Kingdom
  • FIGI BBG00WVTHPN2
  • Industry Technology
Gesamtumsatz
Jahresüberschuss
Unverwässertes Ergebnis je Aktie (Unverwässertes EPS)
Gesamtverschuldung
Freier Cashflow
Zahlungsmittel und Zahlungsmitteläquivalente
Kurs-Gewinn-Verhältnis
-9.65
Preis-Umsatz-Verhältnis
1 541.15

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

Nachrichten